PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025

  • ID: 4334416
  • Report
  • Region: Global
  • 365 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • CytoDyn
  • Gilead Sciences
  • Janssen
  • Merck & Co.
  • TaiMed Biologics
  • MORE
PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025

Summary

Global HIV therapeutics market was worth approximately US$16.3 billion in 2015, and the author projects this market to reach a total of US$22.5 billion in sales by 2025, at a Compound Annual Growth Rate (CAGR) of 3.3%.

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKline’s (GSK’s) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART).

Some of the main drivers of the growth of the HIV market during the forecast period are expected to be -
  • The introduction of novel drugs-most notably, single-tablet regimens (STRs) and nucleotide reverse transcriptase inhibitor (NRTI)-free regimens with improved tolerability, a reduced pill burden, or increased efficacy.
  • An increasing number of people living with HIV who are treated with antiretroviral therapy (ART).
  • Increased efforts to identify new HIV infections through more aggressive screening and diagnostic policies, along with new and more sensitive diagnostic testing tools and methods.
  • Adoption of the test-and-treat approach to increase the number of patients on ART and reduce viral loads.
HIV market is dominated by the Big Pharma players, such as Gilead, ViiV Healthcare (a collaboration between GlaxoSmithKline [GSK], Pfizer, and Shionogi), Janssen, and Merck, and other companies that have carved out a niche in the existing marketplace. While some of the companies involved in the HIV marketplace have invested in their R&D to build exhaustive pipelines spanning all phases of clinical development, others, such as Bristol-Myers Squibb (BMS), moved out of the HIV market in favor of other disease markets, such as oncology.

Two of the most important persistent unmet needs with regard to the current HIV therapies are concerns about drug adverse effects and the need for drugs that are active against drug-resistant strains of HIV. Currently, it is relatively common for drug-resistant viral strains to force physicians to move patients from one therapy to the next, which can result in in the emergence of untreatable strains and restrict the use of the available drugs. This is especially a concern among patients who are treated with a multi-pill regimen, which negatively affects compliance rates.

The report "PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast and Market Analysis to 2025" provides an overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.

In particular, this report provides the following -
  • Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Companies mentioned in this report: Gilead Sciences, ViiV Healthcare,Merck & Co. , Janssen (Johnson & Johnson), Bristol-Myers Squibb, TaiMed Biologics, Cytodyn.

Scope
  • Overview of HIV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
  • Topline HIV market revenue from 2015-2025. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.
  • Key topics covered include current treatment options, unmet needs and opportunities, and the drivers and barriers affecting HIV therapeutics sales in the 9MM.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
  • Analysis of the current and future market competition in the global HIV therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global HIV therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the HIV therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Bristol-Myers Squibb
  • CytoDyn
  • Gilead Sciences
  • Janssen
  • Merck & Co.
  • TaiMed Biologics
  • MORE
1. Table of Contents
1.1 List of Tables
1.2 List of Figures
2. Human Immunodeficiency Virus (HIV): Executive Summary
2.1 HIV Market Will Experience Modest Growth During the Forecast Period
2.2 Companies Leverage Partnerships to Develop New STRs and Fixed-Dose Combinations to Capture HIV Market Share
2.3 While HIV Therapies Continue to Raise the Bar on Efficacy, Safety, and Convenience, Unmet Needs Persist
2.4 Even in the Face of Strong Marketed and Pipeline Products, Opportunities Still Exist for Current and Future Players to Impact the HIV Marketplace
2.5 Novel STRs and FDCs With Improved Efficacy and Safety, and a Decreased Pill Burden, Are Expected to Dominate the Future HIV Treatment Landscape
2.6 What Do Physicians Think?
3. Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4. Disease Overview
4.1 Etiology
4.1.1 The Viral Lifecycle
4.2 Pathophysiology
4.3 Staging and Symptoms
4.3.1 Acute Infection
4.3.2 Chronic Infection
4.3.3 Advanced Infection (AIDS)
4.4 Prognosis
4.5 Quality of Life
5. Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global Trends
5.3.1 US
5.3.2 5EU
5.3.3 Japan, Brazil, and China
5.4 Forecast Methodology
5.4.1 Sources Used
5.4.2 Forecast Assumptions and Methods
5.4.3 Sources Not Used
5.5 Epidemiological Forecast for HIV in the 8MM (2015-2025)
5.5.1 Total Prevalent Cases of HIV
5.5.2 Diagnosed Prevalent Cases of HIV
5.5.3 Age-Specific Diagnosed Prevalent Cases of HIV
5.5.4 Sex-Specific Diagnosed Prevalent Cases of HIV
5.5.5 Age-Standardized Diagnosed Prevalence of HIV
5.5.6 Diagnosed Prevalent Cases of HIV Treated with Antiretroviral Therapy
5.5.7 Diagnosed Prevalent Cases of HIV with Hepatitis B Virus Co-infection
5.5.8 Diagnosed Prevalent Cases of HIV with Hepatitis C Virus Co-infection
5.6 Epidemiological Forecast for HIV in Japan (2015-2025)
5.6.1 20-Year Diagnosed Prevalent Cases of HIV
5.6.2 Age-Specific 20-Year Diagnosed Prevalent Cases of HIV
5.6.3 Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV
5.6.4 Age-Standardized 20-Year Diagnosed Prevalence of HIV
5.6.5 20-Year Diagnosed Prevalent Cases of HIV Treated with Antiretroviral Therapy
5.6.6 20-Year Diagnosed Prevalent Cases of HIV with Hepatitis B Virus Co-infection
5.6.7 20-Year Diagnosed Prevalent Cases of HIV with Hepatitis C Virus Co-infection
5.7 Discussion
5.7.1 Epidemiological Forecast Insight
5.7.2 Limitations of Analysis
5.7.3 Strengths of Analysis
6. Disease Management
6.1 Diagnosis and Treatment Overview
6.1.1 Screening and Diagnosis
6.1.2 Treatment Guidelines and Leading Prescribed Drugs
6.1.3 Clinical Practice
6.2 US
6.2.1 Screening and Diagnosis
6.2.2 Clinical Practice
6.3 5EU
6.3.1 Screening and Diagnosis
6.3.2 Clinical Practice
6.4 Japan
6.4.1 Screening and Diagnosis
6.4.2 Clinical Practice
6.5 Brazil
6.5.1 Screening and Diagnosis
6.5.2 Clinical Practice
6.6 China
6.6.1 Screening and Diagnosis
6.6.2 Clinical Practice
7. Competitive Assessment
7.1 Overview
7.2 Product Profiles - Major Brands, Single-Tablet Regimens
7.2.1 Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate)
7.2.2 Stribild (cobicistat/elvitegravir/emtricitabine/TDF)
7.2.3 Genvoya (cobicistat/elvitegravir/emtricitabine/TAF)
7.2.4 Triumeq (abacavir/dolutegravir/lamivudine)
7.2.5 Complera (emtricitabine/rilpivirine/TDF)
7.2.6 Odefsey (emtricitabine/rilpivirine/TAF)
7.3 Product Profiles - Major Brands, Fixed-Dose NRTI Backbones
7.3.1 Truvada (emtricitabine/TDF)
7.3.2 Descovy (emtricitabine/TAF)
7.4 Product Profiles - Major Brands, Integrase Inhibitors
7.4.1 Tivicay (dolutegravir)
7.4.2 Isentress (raltegravir)
7.5 Product Profiles - Major Brands, Protease Inhibitors
7.5.1 Prezcobix (darunavir/cobicistat)
7.5.2 Evotaz (atazanavir/cobicistat)
7.6 Other Approved Drugs
7.6.1 Overview
8. Unmet Needs Assessment and Opportunity Analysis
8.1 Overview
8.2 Long-Acting Regimens that Require Less-Frequent Administration
8.2.1 Unmet Need
8.2.2 Gap Analysis
8.2.3 Opportunity
8.3 Enhanced Public Awareness Initiatives Focused on Minimizing the Stigma Associated with HIV Infection
8.3.1 Unmet Need
8.3.2 Gap Analysis
8.3.3 Opportunity
8.4 Improved Physician Education Tools That Emphasize the Importance of Early Testing and Diagnosis
8.4.1 Unmet Need
8.4.2 Gap Analysis
8.4.3 Opportunity
8.5 Safe and Efficacious Therapies for Patients with Drug-Resistant HIV Strains
8.5.1 Unmet Need
8.5.2 Gap Analysis
8.5.3 Opportunity
8.6 Therapies with Improved Safety and Tolerability Profiles
8.6.1 Unmet Need
8.6.2 Gap Analysis
8.6.3 Opportunity
8.7 Progress Towards a Functional Cure
8.7.1 Unmet Need
8.7.2 Gap Analysis
8.7.3 Opportunity
9. Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.2.1 Bictegravir/Emtricitabine/TAF
9.2.2 Dolutegravir/Lamivudine
9.2.3 Cobicistat/Darunavir/Emtricitabine/TAF
9.2.4 Doravirine/Lamivudine/TDF
9.2.5 Dolutegravir/Rilpivirine
9.2.6 Cabotegravir/Rilpivirine
9.2.7 Fostemsavir
9.2.8 Ibalizumab
9.2.9 PRO-140
9.3 Other Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Company Profiles
10.3.1 Gilead Sciences
10.3.2 ViiV Healthcare
10.3.3 Janssen
10.3.4 Merck & Co.
10.3.5 Bristol-Myers Squibb
10.3.6 Minor and Emerging Players
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers - Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 Brazil
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers
11.6 China
11.6.1 Forecast
11.6.2 Key Events
11.6.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Forecasting Methodology
12.4.1 Total and Diagnosed Prevalent Cases of HIV (8MM)
12.4.2 20-Year Diagnosed Prevalent Cases of HIV (Japan)
12.4.3 Diagnosed Prevalent Cases of HIV Treated with ART
12.4.4 Drugs Included in Each Therapeutic Class
12.4.5 Launch and Patent Expiry Dates
12.4.6 General Pricing Assumptions
12.4.7 Individual Drug Assumptions
12.4.8 Generic Erosion
12.4.9 Pricing of Pipeline Agents
12.5 Primary Research - KOLs and Payers Interviewed for this Report
12.5.1 KOLs
12.5.2 Payers
12.6 Primary Research - Prescriber Survey
12.7 About the Authors
12.7.1 Analyst
12.7.2 Therapy Area Director
12.7.3 Epidemiologists
12.7.4 Global Director of Therapy Analysis and Epidemiology
12.7.5 Global Head and EVP of Healthcare Operations and Strategy
12.8 About
12.9 Contact Us
12.10 Disclaimer

1.1 List of Tables
Table 1: HIV: Key Metrics in the Nine Major Pharmaceutical Markets
Table 2: CDC and WHO Staging Classification of HIV-1 Infection in Patients =6 Years
Table 3: Symptoms of Acute, Chronic, and Advanced Stages of HIV Infection
Table 4: Risk Factors and Comorbidities for HIV
Table 5: 5EU, Total Prevalence of HIV in Men and Women (%), All Ages, Selected Years, 2001-2015
Table 6: 8MM, Sources of HIV Total Prevalence Data
Table 7: 8MM, Sources of HIV Diagnosed Prevalence Data
Table 8: Japan, Sources Used to Forecast the 20-Year Diagnosed Prevalent Cases of HIV in Japan
Table 9: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV on ART
Table 10: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HBV Co-infection
Table 11: 9MM, Sources Used to Forecast Diagnosed Prevalent Cases of HIV with HCV Co-infection
Table 12: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025
Table 13: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025
Table 14: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015, Cases (N) and Proportions (Row %)
Table 15: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, 2015 (Row %)
Table 16: 8MM, Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes, 2015-2025, Cases (N) and Proportions (%)
Table 17: 8MM, Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015-2025, Cases (N) and Proportions (%)
Table 18: 8MM, Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015-2025, Cases (N) and Proportions (%)
Table 19: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025
Table 20: Japan, Age-Specific 20-Year Diagnosed Prevalent Cases of HIV, Both Sexes, N, 2015 (Row %)
Table 21: Japan, Sex-Specific 20-Year Diagnosed Prevalent Cases of HIV, All Ages, N, 2015 (Row %)
Table 22: Japan, 20-Year Diagnosed Prevalent HIV Cases Treated with ART, All Ages, Both Sexes 2015-2025, Cases (N) and Proportions (%)
Table 23: Japan, 20-Year Diagnosed Prevalent HIV Cases with HBV Co-infection, All Ages, Both Sexes, 2015-2025, Cases (N) and Proportions (%)
Table 24: Japan, 20-Year Diagnosed Prevalent HIV Cases with HCV Co-infection, All Ages, Both Sexes, 2015-2025, Cases (N) and Proportions (%)
Table 25: Treatment Guidelines for HIV-1 Used in the 9MM
Table 26: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2015
Table 27: Most Commonly Prescribed Drugs for HIV-1 by Class in the 9MM, 2016
Table 28: Diagnosis and Treatment of HIV Infection, Country Profile - US
Table 29: Switching of ART Regimens in the US, 2015
Table 30: Diagnosis and Treatment of HIV Infection, Country Profile - 5EU
Table 31: CD4+ Thresholds and Corresponding Recommendations for the Initiation of ART in Asymptomatic Patients in the 5EU
Table 32: Switching of ART Regimens in the 5EU, 2015
Table 33: Diagnosis and Treatment of HIV Infection, Country Profile - Japan
Table 34: Switching of ART Regimens in Japan, 2015
Table 35: Diagnosis and Treatment of HIV Infection, Country Profile - Brazil
Table 36: Switching of ART Regimens in Brazil, 2015
Table 37: Diagnosis and Treatment of HIV Infection, Country Profile - China
Table 38: Switching of ART Regimens in China, 2015
Table 39: Leading Branded Treatments for HIV, 2016
Table 40: Product Profile - Atripla
Table 41: Efficacy of Atripla Compared with Combivir + Sustiva
Table 42: Safety of Atripla - Frequency of AEs Compared with Combivir + Sustiva
Table 43: Atripla SWOT Analysis, 2016
Table 44: Product Profile - Stribild
Table 45: Pivotal Phase III Trials of Stribild in Treatment-Naïve Patients
Table 46: Stribild’s Adverse Reactions - Pooled Results From Two Phase III Clinical Trials
Table 47: Stribild SWOT Analysis, 2016
Table 48: Product Profile - Genvoya
Table 49: Efficacy of Genvoya and Stribild in Studies 104 and 111
Table 50: Adverse Events Associated with Genvoya vs. Stribild Therapy in Two Phase III Clinical Studies
Table 51: Genvoya SWOT Analysis, 2016
Table 52: Product Profile - Triumeq
Table 53: Virologic Efficacy of Triumeq in the Phase III SINGLE Study
Table 54: Triumeq’s Safety - Adverse Reactions Reported at 96 Weeks in the SINGLE Study
Table 55: Triumeq SWOT Analysis, 2016
Table 56: Product Profile - Complera
Table 57: ECHO and THRIVE Studies of the Complera and Atripla Multi-tablet Regimens
Table 58: Complera SWOT Analysis, 2016
Table 59: Product Profile - Odefsey
Table 60: Safety of Odefsey - Frequency of AEs
Table 61: Odefsey SWOT Analysis, 2016
Table 62: Product Profile - Truvada
Table 63: Truvada’s Efficacy - Results of the SWIFT Trial at 48 Weeks
Table 64: Truvada SWOT Analysis, 2016
Table 65: Product Profile - Descovy
Table 66: Safety of Descovy - Frequency of AEs
Table 67: Descovy SWOT Analysis, 2016
Table 68: Product Profile - Tivicay
Table 69: Pivotal Phase III Trials of Tivicay
Table 70: Tivicay’s Safety - Adverse Reactions Reported in the 48-Week SINGLE Study
Table 71: Tivicay SWOT Analysis, 2016
Table 72: Product Profile - Isentress
Table 73: Percentage of Patients with HIV-1 RNA Levels < 50 Copies/mL from the SMARTMRK Study
Table 74: Isentress’ Safety - Adverse Reactions Reported in the SMARTMRK Study
Table 75: Isentress SWOT Analysis, 2016
Table 76: Product Profile - Prezcobix
Table 77: Efficacy of Prezcobix in the Phase III Trial
Table 78: Prezcobix SWOT Analysis, 2016
Table 79: Product Profile - Evotaz
Table 80: Efficacy of BMS’ Evotaz in the Phase III Study
Table 81: Evotaz SWOT Analysis, 2016
Table 82: Other Approved HIV Drugs
Table 83: Unmet Need and Opportunity in HIV
Table 84: Key Late-Stage Pipeline Agents for HIV Therapeutics, 2016
Table 85: Comparison of Therapeutic Classes in Development for HIV, 2015-2025
Table 86: Product Profile - Bictegravir/Emtricitabine/TAF
Table 87: Gilead’s Bictegravir/Emtricitabine/TAF - Phase III Clinical Trials
Table 88: Bictegravir/Emtricitabine/TAF SWOT Analysis, 2016
Table 89: Product Profile - Dolutegravir/Lamivudine
Table 90: ViiV’s Dolutegravir/Lamivudine - Phase III Clinical Trials
Table 91: Dolutegravir/Lamivudine Safety - Adverse Reactions Reported at 24 Weeks - PADDLE Study
Table 92: Dolutegravir/Lamivudine SWOT Analysis, 2016
Table 93: Product Profile - Cobicistat/Darunavir/Emtricitabine/TAF
Table 94: Janssen’s Cobicistat/Darunavir/Emtricitabine/TAF - Phase III Clinical Trials
Table 95: Cobicistat/Darunavir/Emtricitabine/TAF SWOT Analysis, 2016
Table 96: Product Profile - Doravirine/Lamivudine/TDF
Table 97: Efficacy Results of a Phase II Dose-Ranging Study of Doravirine Compared with a Standard Dose of Efavirenz
Table 98: Doravirine/Lamivudine/TDF SWOT Analysis, 2016
Table 99: Product Profile - Dolutegravir/Rilpivirine
Table 100: Tivicay’s Safety - Adverse Reactions Reported in the 48-Week SINGLE Study
Table 101: Dolutegravir/Rilpivirine SWOT Analysis, 2016
Table 102: Product Profile - Cabotegravir/Rilpivirine
Table 103: Cabotegravir/Rilpivirine SWOT Analysis, 2016
Table 104: Product Profile - Fostemsavir
Table 105: Fostemsavir SWOT Analysis, 2016
Table 106: Product Profile - Ibalizumab
Table 107: TaiMed’s and Theratechnologies’ Ibalizumab - Phase IIb Clinical Trial Outcomes
Table 108: Ibalizumab SWOT Analysis, 2016
Table 109: Product Profile - PRO-140
Table 110: PRO-140 SWOT Analysis, 2016
Table 111: Other Drugs in Phase II of Clinical Development for HIV, 2016
Table 112: Key Companies in the HIV Market in the 9MM, 2016
Table 113: Gilead Sciences’ HIV Portfolio Assessment, 2016
Table 114: ViiV Healthcare’s HIV Portfolio Assessment, 2016
Table 115: Janssen’s HIV Portfolio Assessment, 2016
Table 116: Merck & Co.’s HIV Portfolio Assessment, 2016
Table 117: BMS’ HIV Portfolio Assessment, 2016
Table 118: Global Sales Forecasts ($m) for HIV, 2015-2025
Table 119: HIV Therapeutics Market - Global Drivers and Barriers, 2015-2025
Table 120: Sales Forecasts ($m) for HIV in the US, 2015-2025
Table 121: Key Events Impacting Sales for HIV Therapeutics in the US, 2015-2025
Table 122: HIV Therapeutics Market - Drivers and Barriers in the US, 2015?2025
Table 123: Number of People Living with HIV Who Received ART in the 5EU, and Sales of HIV Therapeutics, 2015
Table 124: Sales Forecasts ($m) for HIV in the 5EU, 2015-2025
Table 125: Key Events Impacting Sales for HIV in the 5EU, 2015-2025
Table 126: HIV Therapeutics Market - Drivers and Barriers in the 5EU, 2015?2025
Table 127: Sales Forecasts ($m) for HIV in Japan, 2015-2025
Table 128: Key Events Impacting Sales for HIV Therapeutics in Japan, 2015-2025
Table 129: Sales Forecasts ($m) for HIV in Brazil, 2015-2025
Table 130: Key Events Impacting Sales for HIV Therapeutics in Brazil, 2015-2025
Table 131: HIV Therapeutics Market - Drivers and Barriers in Brazil, 2015?2025
Table 132: Sales Forecasts ($m) for HIV in China, 2015-2025
Table 133: Key Events Impacting Sales of HIV Therapeutics in China, 2015-2025
Table 134: HIV Therapeutics Market - Drivers and Barriers in China, 2015?2025
Table 135: Key Historical and Projected Launch Dates for HIV Therapeutics Across the 9MM
Table 136: Patent Expiry Dates for HIV Therapeutics Across the 9MM
Table 137: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

1.2 List of Figures
Figure 1: Global Sales for HIV by Country/Region, 2015 and 2025
Figure 2: Company Portfolio Gap Analysis in HIV, 2015-2025
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015-2025
Figure 4: Cartoon Depicting the HIV Lifecycle
Figure 5: Global Overview of HIV, Men and Women, All Ages, 1990-2015
Figure 6: 8MM, Total Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025
Figure 7: 8MM, Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025
Figure 8: 8MM, Age-Specific Diagnosed Prevalent Cases of HIV, Both Sexes, N, Select Years, 2015-2025
Figure 9: 8MM, Sex-Specific Diagnosed Prevalent Cases of HIV, All Ages, N, Select Years, 2015-2025
Figure 10: 8MM, Age-Standardized Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015
Figure 11: Japan, 20-Year Diagnosed Prevalent Cases of HIV, All Ages, Both Sexes, N, Select Years, 2015-2025
Figure 12: Japan, Age-Standardized 20-Year Diagnosed Prevalence of HIV (%), All Ages, by Sex, 2015
Figure 13: HIV Disease Management Flowchart
Figure 14: HIV - Phase III Pipeline, 2016
Figure 15: Competitive Assessment of Late-Stage Pipeline Agents in HIV, 2015-2025
Figure 16: Company Portfolio Gap Analysis in HIV, 2015-2025
Figure 17: Global Sales for HIV by Country/Region, 2015 and 2025
Figure 18: Global Sales for HIV by Drug Class, 2015 and 2025
Figure 19: Sales for HIV by Drug Class in the US, 2015 and 2025
Figure 20: Sales for HIV by Drug Class in the 5EU, 2015 and 2025
Figure 21: Sales for HIV by Drug Class in Japan, 2015 and 2025
Figure 22: Sales for HIV by Drug Class in Brazil, 2015 and 2025
Figure 23: Sales for HIV by Drug Class in China, 2015 and 2025
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Gilead Sciences
  • ViiV Healthcare
  • Janssen
  • Merck & Co.
  • Bristol-Myers Squibb
  • TaiMed Biologics
  • CytoDyn
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll